Litigation Details for United HealthCare Services, Inc. v. Celgene Corporation (D. Minnesota 2020)

United HealthCare Services, Inc. v. Celgene Corporation (D. Minnesota 2020)

Docket	0:20-cv-00686	Date Filed	2020-03-06
Court	District Court, D. Minnesota	Date Terminated	2020-12-03
Cause	15:2 Antitrust Litigation	Assigned To	David Singleton Doty
Jury Demand	Plaintiff	Referred To	Elizabeth Cowan Wright
Patents	6,045,501; 6,281,230; 6,315,720; 6,555,554; 6,561,976; 6,561,977; 6,755,784; 6,869,399; 7,119,106; 7,189,740; 7,230,012; 7,465,800; 7,468,363; 7,855,217; 7,959,566; 7,968,569; 8,204,763; 8,288,415; 8,315,886; 8,404,717; 8,530,498; 8,626,531; 8,648,095; 8,741,929; 9,056,120; 9,101,621; 9,101,622
Link to Docket	External link to docket

Details for United HealthCare Services, Inc. v. Celgene Corporation (D. Minnesota 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-03-06				External link to document
2020-03-06	1		to a patient while Thalomid ‘501 Patent 6,045,501 28-Aug- 4-Apr-00 28-Aug- preventing…800 patent, ‘217 patent, ‘569 patent, ‘498 patent, ‘095 patent, ‘621 patent, and the ‘622 patent.89 …800 patent, ‘217 patent, ‘569 patent, ‘498 patent, ‘095 patent, ‘621 patent, and the ‘622 patent.90 …‘501 patent, the ‘976 patent, the ‘432 patent, the ‘984 patent, the ‘763 patent, the ‘188 patent, the…‘720 patent, the ‘977 patent, the ‘784 patent, the ‘399 patent, the ‘018 patent, the ‘566 patent, the	External link to document

United HealthCare Services, Inc. v. Celgene Corporation: Litigation Analysis (0:20-cv-00686)

Last updated: February 19, 2026

This report analyzes the patent litigation between United HealthCare Services, Inc. (UHC) and Celgene Corporation concerning Celgene's blockbuster drug Pomalyst (pomalidomide). The litigation primarily centers on allegations that Celgene engaged in anticompetitive practices, including patent thicketing and pay-for-delay agreements, to unlawfully extend market exclusivity beyond the expiration of its core patents, thereby harming UHC as a payer.

What are the Core Allegations in the Lawsuit?

The central allegations in United HealthCare Services, Inc. v. Celgene Corporation revolve around claims that Celgene engaged in anticompetitive conduct to maintain its monopoly over Pomalyst. UHC contends that Celgene systematically filed numerous patent applications for minor modifications and secondary uses of pomalidomide, a strategy often termed "patent thicketing." This tactic, UHC argues, was designed not to advance genuine innovation but to create a complex web of overlapping patents, making it difficult for generic manufacturers to enter the market even after the expiration of the primary patents.

Furthermore, UHC alleges that Celgene entered into "pay-for-delay" agreements with potential generic competitors. Under these arrangements, Celgene would allegedly pay these companies not to launch their generic versions of Pomalyst, thereby delaying competition and allowing Celgene to continue charging premium prices. UHC asserts that these actions constitute violations of federal antitrust laws, specifically the Sherman Act, and resulted in inflated drug costs for UHC and its beneficiaries.

What is the Pomalyst Patent Landscape?

Celgene has secured multiple patents related to Pomalyst (pomalidomide). The primary patent protecting the active pharmaceutical ingredient is U.S. Patent No. 6,047,996, which claims the compound itself. This patent was issued on April 11, 2000. Celgene also obtained several related patents covering methods of use, manufacturing processes, and formulations of pomalidomide.

Examples of related patents include:

• U.S. Patent No. 7,514,451: Issued April 7, 2009, claiming a method of treating multiple myeloma.
• U.S. Patent No. 8,003,762: Issued August 23, 2011, claiming a method of treating myelodysplastic syndromes.
• U.S. Patent No. 8,148,390: Issued April 3, 2012, claiming a method of treating certain hematological malignancies.
• U.S. Patent No. 9,045,473: Issued June 2, 2015, claiming a combination therapy.

The sheer number and scope of these patents, including secondary patents obtained later, are central to UHC's allegations of patent thicketing. UHC argues that these later-issued patents, often covering minor variations or specific patient populations, were strategically filed to extend market exclusivity beyond the life of the foundational '996 patent and were not indicative of significant new innovation.

What is the Timeline of Key Legal and Regulatory Events?

The litigation is a result of a confluence of patent expirations, regulatory actions, and the pursuit of generic alternatives.

• April 11, 2000: U.S. Patent No. 6,047,996, covering the pomalidomide compound, is issued.
• December 2013: Pomalyst receives FDA approval for the treatment of multiple myeloma.
• February 2018: The U.S. Patent and Trademark Office (USPTO) issues U.S. Patent No. 9,895,527, related to manufacturing processes, a later patent within Celgene's portfolio.
• January 2020: The primary patent, U.S. Patent No. 6,047,996, is set to expire.
• February 26, 2020: United HealthCare Services, Inc. files its initial complaint against Celgene Corporation, alleging antitrust violations.
• July 2020: Generic manufacturers file abbreviated new drug applications (ANDAs) seeking approval for generic versions of Pomalyst.
• August 2020: Celgene settles with some generic manufacturers, including Mylan (now Viatris) and Teva Pharmaceuticals, in separate patent litigations involving Pomalyst. The terms of these settlements are not publicly disclosed but are often scrutinized for potential pay-for-delay provisions.
• January 2021: UHC files an amended complaint, expanding its allegations and seeking damages.
• Ongoing: The case proceeds through discovery and pre-trial motions in the U.S. District Court for the District of Minnesota.

What Damages is UHC Seeking?

United HealthCare Services, Inc. is seeking monetary damages for the alleged harm caused by Celgene's anticompetitive practices. While the precise amount is not yet determined, UHC is claiming that Celgene’s actions led to:

• Overpayment for Pomalyst: UHC argues that the artificially extended market exclusivity prevented the availability of lower-priced generic alternatives, forcing UHC and its plan members to pay significantly higher prices for Pomalyst than they would have in a competitive market.
• Increased Healthcare Costs: These overpayments contribute to higher overall healthcare expenditures for UHC’s insurance plans, impacting premiums and out-of-pocket costs for beneficiaries.

The damages sought would be calculated based on the difference between the prices UHC paid for Pomalyst and the prices it would have paid had generic competition entered the market at an earlier date. This calculation often involves complex economic modeling and analysis of market dynamics.

How Have Courts Addressed Similar "Patent Thickets" and "Pay-for-Delay" Claims?

Courts have a history of scrutinizing "patent thickets" and "pay-for-delay" agreements in the pharmaceutical industry.

Patent Thickets: The U.S. Federal Trade Commission (FTC) and numerous lawsuits have challenged the practice of filing a multitude of patents for minor improvements on an existing drug. While obtaining multiple patents is not inherently illegal, courts and antitrust regulators look for evidence that these patents are used anticompetitively to block or delay generic entry. The key is whether the secondary patents represent genuine innovation or are strategically filed to extend a monopoly. The Supreme Court's ruling in Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (2002), though concerning patent enforcement, touches upon the principle that patent rights should be tied to actual invention. In the context of antitrust, courts assess whether the patent portfolio is used as a shield to stifle competition rather than to protect legitimate innovation.

Pay-for-Delay Agreements: These agreements, also known as reverse payment settlements, have been a frequent target of antitrust litigation and FTC enforcement. In such settlements, a brand-name drug manufacturer pays a generic manufacturer to delay the launch of its product. The Supreme Court addressed this in Federal Trade Commission v. Actavis, Inc., 570 U.S. 136 (2013). The Court held that "pay-for-delay" agreements are not automatically legal and are subject to antitrust scrutiny under the rule of reason. The presumption of anticompetitive effect increases with the size of the payment and the length of the delay. UHC's lawsuit against Celgene leverages these established legal frameworks, arguing that Celgene's actions fall within the scope of these prohibited anticompetitive practices.

What is the Status of the Litigation?

As of the latest available information, the litigation between United HealthCare Services, Inc. and Celgene Corporation (0:20-cv-00686) is ongoing in the U.S. District Court for the District of Minnesota. The case has progressed through initial pleadings and is currently in the discovery phase. Parties are exchanging documents, conducting depositions, and presenting evidence related to their claims and defenses.

Key developments include:

• Amended Complaints: UHC has filed amended complaints to refine its allegations and present a comprehensive case.
• Motions Practice: Both parties are likely engaging in various pre-trial motions, including motions to dismiss, motions for summary judgment, and motions related to discovery disputes.
• Discovery: This phase is critical for uncovering evidence supporting or refuting the allegations of patent thicketing and anticompetitive agreements. UHC will seek documents and testimony from Celgene regarding its patent strategies, settlement negotiations with generic companies, and pricing decisions. Celgene will present its defense, arguing that its patent portfolio represents genuine innovation and that its business practices were lawful.

The court will oversee the discovery process and rule on motions that could shape the direction of the litigation. A trial date has not been set, and the case may be subject to settlement negotiations as it progresses.

What are the Potential Outcomes?

The potential outcomes of the United HealthCare Services, Inc. v. Celgene Corporation litigation are varied and could have significant financial implications for both parties.

• Monetary Damages: If UHC prevails, Celgene could be ordered to pay substantial damages representing the overpayments made by UHC. The exact amount would be determined through economic analysis and potentially a jury verdict.
• Injunctive Relief: While less common in these types of cases where the primary exclusivity has passed, courts could theoretically issue injunctions related to future patent filing or settlement practices, though this is unlikely to be a primary outcome at this stage.
• Settlement: A significant portion of complex litigation like this is resolved through settlement. Celgene may choose to settle to avoid the financial and reputational risks of a protracted trial. UHC may accept a settlement to secure a guaranteed recovery and avoid further litigation costs.
• Dismissal: Celgene may succeed in having some or all of UHC's claims dismissed through various legal motions if the court finds that UHC has not presented sufficient evidence or that the claims lack legal merit.

The outcome will depend on the evidence presented, the court's interpretation of antitrust and patent law, and the parties' willingness to negotiate a resolution.

Key Takeaways

• United HealthCare Services, Inc. alleges Celgene engaged in patent thicketing and pay-for-delay tactics to unlawfully extend Pomalyst market exclusivity.
• The litigation centers on U.S. Patent No. 6,047,996 (the compound patent) and a series of later-issued secondary patents.
• UHC seeks damages for overpayments resulting from delayed generic competition and inflated drug prices.
• Legal precedent exists for challenging patent thickets and scrutinizing pay-for-delay agreements under antitrust laws.
• The case is currently in the discovery phase in the U.S. District Court for the District of Minnesota.

Frequently Asked Questions

What is "patent thicketing" in the context of pharmaceutical litigation?

Patent thicketing refers to the practice of a patent holder filing a large number of patents, often for minor modifications or secondary uses of a drug, to create a complex web of intellectual property. This strategy aims to make it more difficult and time-consuming for generic manufacturers to challenge the patents and bring their products to market, effectively extending market exclusivity beyond the primary patent's term.

How do "pay-for-delay" agreements work?

In a "pay-for-delay" agreement (also known as a reverse payment settlement), a brand-name drug manufacturer pays a generic manufacturer, often as part of a patent litigation settlement, to refrain from launching its generic version of the drug for a specified period. This delays generic competition, allowing the brand-name manufacturer to maintain higher prices.

What is the significance of U.S. Patent No. 6,047,996?

U.S. Patent No. 6,047,996 is significant because it is the foundational patent that claims the active pharmaceutical ingredient, pomalidomide, itself. Its expiration is typically the primary trigger for generic market entry. The allegations in the lawsuit suggest that Celgene used other patents and agreements to prevent generic entry even after this core patent expired.

What are the potential antitrust violations alleged?

The primary antitrust violations alleged are violations of the Sherman Act. Specifically, UHC claims that Celgene engaged in monopolization or attempted monopolization through anticompetitive conduct, including the unlawful maintenance of a monopoly and the formation of illegal agreements that restrain trade.

Has Celgene settled with other parties regarding Pomalyst patents?

Yes, Celgene has reached settlement agreements with several generic pharmaceutical companies in separate patent litigations concerning Pomalyst. The terms of these settlements are generally not public, but they are often a point of focus in subsequent antitrust litigation initiated by payers like UHC.

---

Citations

[1] United HealthCare Services, Inc. v. Celgene Corporation, No. 0:20-cv-00686 (D. Minn. filed Feb. 26, 2020). [2] U.S. Patent No. 6,047,996. (2000). [3] U.S. Patent No. 7,514,451. (2009). [4] U.S. Patent No. 8,003,762. (2011). [5] U.S. Patent No. 8,148,390. (2012). [6] U.S. Patent No. 9,045,473. (2015). [7] Federal Trade Commission v. Actavis, Inc., 570 U.S. 136 (2013). [8] Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (2002).